StreetInsider.com News Articles

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Thu, 11 Jun 2026 05:32:57 -0400

(Updated - June 11, 2026 5:32 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Buy rating.

The analyst comments "NervGen is advancing candidates for the treatment of neurotraumatic and neurologic conditions. Lead asset NVG-291 is set to begin a Ph. III trial in mid-2026 for chronic incomplete tetraplegia, after demonstrated encouraging efficacy in Ph. I/II study. Enrollment is slated to complete mid-2027 with data in early '28. We see our $1.1B peak estimate as achievable given favorable KOL commentary. Buy."

For an analyst ratings summary and ratings history on NervGen Pharma Corp click

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Thu, 11 Jun 2026 05:32:57 -0400

(Updated - June 11, 2026 5:32 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Buy rating.

For an analyst ratings summary and ratings history on NervGen Pharma Corp click

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Thu, 11 Jun 2026 05:32:57 -0400

(Updated - June 11, 2026 5:32 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Buy rating.

For an analyst ratings summary and ratings history on NervGen Pharma Corp click

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Thu, 11 Jun 2026 05:32:57 -0400

(Updated - June 11, 2026 5:32 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Buy rating.

For an analyst ratings summary and ratings history on NervGen Pharma Corp click

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Mon, 01 Jun 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260601/26585204.html

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Mon, 01 Jun 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260601/26585204.html

Form EFFECT NERVGEN PHARMA CORP.

Wed, 27 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260527/26552941.html

Form EFFECT NERVGEN PHARMA CORP.

Wed, 27 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260527/26552941.html

Form 6-K NERVGEN PHARMA CORP. For: May 26

Tue, 26 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260526/26550660.html

Form 6-K NERVGEN PHARMA CORP. For: May 26

Tue, 26 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260526/26550660.html

Form SUPPL NERVGEN PHARMA CORP.

Tue, 26 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260526/26550590.html

Form SUPPL NERVGEN PHARMA CORP.

Tue, 26 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260526/26550590.html

Form F-X NERVGEN PHARMA CORP. Filed by: NERVGEN PHARMA CORP.

Tue, 26 May 2026 09:40:00 -0400

si-local-file:///var/storage/secattach/20260526/26547125.html

Form F-X NERVGEN PHARMA CORP. Filed by: NERVGEN PHARMA CORP.

Tue, 26 May 2026 09:40:00 -0400

si-local-file:///var/storage/secattach/20260526/26547125.html

Form F-10 NERVGEN PHARMA CORP.

Tue, 26 May 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260526/26547033.html

Form F-10 NERVGEN PHARMA CORP.

Tue, 26 May 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260526/26547033.html

NervGen reports positive biomechanical gait analysis data for NVG-291

Tue, 26 May 2026 07:15:17 -0400

NervGen Pharma Corp. (NASDAQ: NGEN) announced results from independent, blinded biomechanical gait analyses of its drug candidate NVG-291 in patients with chronic spinal cord injury. The analyses were conducted as part of the company's Phase 1b/2a CONNECT SCI study.

The biomechanical analyses were performed by Newton Tech using video-based motion capture technology to evaluate gait quality. The study measured coordination, mechanical effort, and postural stability as indicators of neural recovery versus compensatory movement patterns.

According to the company's announcement, NVG-291 demonstrated statistically significant improvement in gait quality compared to placebo (p=0.0197) based on a Global Statistical Test. The analysis showed that all

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Tue, 26 May 2026 07:15:00 -0400

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit.
Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).
These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study.

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Tue, 26 May 2026 07:15:00 -0400

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit.
Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).
These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study.

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Tue, 26 May 2026 07:15:00 -0400

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit.
Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).
These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study.

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Tue, 26 May 2026 07:15:00 -0400

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit.
Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).
These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study.

Form 6-K NERVGEN PHARMA CORP. For: May 22

Fri, 22 May 2026 17:24:00 -0400
si-local-file:///var/storage/secattach/20260522/26542931.html

Form 6-K NERVGEN PHARMA CORP. For: May 22

Fri, 22 May 2026 17:24:00 -0400
si-local-file:///var/storage/secattach/20260522/26542931.html

Form SUPPL NERVGEN PHARMA CORP.

Fri, 22 May 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260522/26542897.html

Form SUPPL NERVGEN PHARMA CORP.

Fri, 22 May 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260522/26542897.html

StreetInsider.com News Articles

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Form EFFECT NERVGEN PHARMA CORP.

Form EFFECT NERVGEN PHARMA CORP.

Form 6-K NERVGEN PHARMA CORP. For: May 26

Form 6-K NERVGEN PHARMA CORP. For: May 26

Form SUPPL NERVGEN PHARMA CORP.

Form SUPPL NERVGEN PHARMA CORP.

Form F-X NERVGEN PHARMA CORP. Filed by: NERVGEN PHARMA CORP.

Form F-X NERVGEN PHARMA CORP. Filed by: NERVGEN PHARMA CORP.

Form F-10 NERVGEN PHARMA CORP.

Form F-10 NERVGEN PHARMA CORP.

NervGen reports positive biomechanical gait analysis data for NVG-291

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Form 6-K NERVGEN PHARMA CORP. For: May 22

Form 6-K NERVGEN PHARMA CORP. For: May 22

Form SUPPL NERVGEN PHARMA CORP.

Form SUPPL NERVGEN PHARMA CORP.